Mp87-08 synthesis and evaluation of structure-activity relationship of derivatives of a selective inhibitor for erg positive prostate cancer cells
The ETS Related Gene (ERG) is dormant and non-detectable in normal prostate. Despite of significant advancements in prostate cancer treatment in recent years, hormone therapy remains the main treatment for advanced CaP. Unfortunately, late stage prostate cancers are highly prone to treatment resistance. Thus, there is an urgent need to develop effective and novel inhibitors to target CaP driver genes in the early stages of prostate tumorigenesis. ERG oncoprotein and ERG dependent pathways are promising targets for early stage cancer therapy.
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Charles P Xavier, Ahmed A Mohamed, Nishat Seraj, Vineet Kumar, Gauthaman Sukumar, Shyh-Han Tan, Lakshmi Ravindranath, Taduru Sreenath, David G McLeod, Igner L Rosner, Gyorgy Petrovics, Meera Srivastava, Jeffery Strovel, Nicole A LaRonde, Clifton L Dalgard Tags: Prostate Cancer: Advanced (including Drug Therapy) IV Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Genetics | Hormonal Therapy | Hormones | Prostate Cancer | Urology & Nephrology